---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-23-000077"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:42:57.792680+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Elicio Therapeutics Q3 net loss $10.7M; ELI-002 RFS 16.3 months, Phase 2 planned early 2024

## Summary
- Net loss of $10.7M ($1.27/sh) vs $7.2M loss ($22.67/sh) in Q3 2022; cash $14.1M vs $6.2M year-end 2022.
- ELI-002 2P showed median relapse-free survival of 16.3 months; T-cell response correlated with 86% risk reduction (HR 0.14, p=0.013).
- ELI-002 7P Phase 2 monotherapy trial in adjuvant PDAC to start early 2024; interim analysis expected Q1 2025.
- R&D expense $7.3M (+58% YoY) and G&A $3.5M (+198% YoY) driven by public company costs and trial expansion.

## SEC filing metadata
- accession: 0001601485-23-000077
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148523000077/0001601485-23-000077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148523000077/angn-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-23-000077
- JSON: https://secwatch.observer/filing/0001601485-23-000077.json
- Plain text: https://secwatch.observer/filing/0001601485-23-000077.txt

## Key facts
- Earnings Releases
  Elicio Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.
  - Period: third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 9, 2023, Elicio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601485/000160148523000077/0001601485-23-000077-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.